Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 386

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 386
---
 $          | 14.22 |
| Unvested Balance at December 31, 2023    |     |                |   7 |   |     | $          | 11.43 |
| Granted                                  |     |                |   — |   |     | $          |     — |
| Vested                                   |     |                |  (0 | ) |     | $          | 23.15 |
| Unvested balance as of December 31, 2024 |     |                |   7 |   |     | $          | 11.15 |

During the year ended December 31, 2023, the Company agreed with its Chief Medical Officer to accelerate the vesting of less than 0.01 million shares of restricted stock. The Company recorded $0.1 million of stock-based compensation expense within research and development in the accompanying statement of operations for the year ended December 31, 2023. As part of the Series C Offering, the Company modified certain restricted stock awards that were previously awarded to employees and non-employeesto accelerate the vesting from six months after the consummation of an IPO to immediate vesting. An aggregate amount of 0.01 million restricted stock vested upon the closing of the Series C Offering in August 2023. The Company recorded $0.1 million and less than $0.01 million of stock-based compensation with general and administrative and research and development, respectively in the accompanying statement of operations for the year ended December 31, 2023. The total fair value of restricted stock that vested during the years ended December 31, 2024 and 2023 was $0.2 million and less than $0.1 million, respectively. Stock-based compensation related to restricted stock is recorded in the accompanying statements of operations as follows (in thousands):

|                                        |     | Year ended   
 December 31, | 2024 |     |   | 2023 |
|:---------------------------------------|:----|:-------------|-----:|:----|:--|-----:|
| Research and development               |     | $            |    2 |     | $ |   99 |
| General and administrative             |     |              |    1 |     |   |  132 |
| Total stock-based compensation expense |     | $            |    3 |     | $ |  231 |

F-30

LB Pharmaceuticals Inc

Notes to Financial Statements

As of